Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Unveiling the Uncommon: Pyoderma Gangrenosum as an Extraintestinal Complication of Ulcerative Colitis
Publication Year: 2025 Source: ACG Case Rep J PMID: 40242300
Pyoderma gangrenosum (PG) is a rare inflammatory skin disorder characterized by neutrophil accumulation, commonly appearing as erythematous papules or pustules that can coalesce into extensive ulcers. It is the second most common dermatologic manifestation of inflammatory bowel disease, though it affects <1% of patients with inflammatory bowel disease. We present …
Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease
Publication Year: 2025 Source: ACS Pharmacol Transl Sci PMID: 40242579 DOI: 10.1021/acsptsci.5c00068
Inflammatory bowel disease (IBD), a chronic, progressive, and recurrent gastrointestinal inflammatory disorder, poses a significant threat to global health and exerts an adverse effect on the quality of life. Currently, there is a lack of effective therapies for IBD. Developing novel targeted therapies for IBD, particularly orally effective therapeutics, is …
Right-Sided Dysplasia in Inflammatory Bowel Disease Is Not Associated with Conventional Risk Factors for Neoplasia
Publication Year: 2025 Source: Gastroenterol Insights PMID: 40242653 DOI: 10.3390/gastroent16020014
INTRODUCTION: In the general population, right I-sided dysplasia presents a higher risk for colorectal cancer (CRC) and metachronous dysplasia compared to left (L)-sided dysplasia. Given that patients with inflammatory bowel disease (IBD) are at higher risk for dysplasia than the general population, we sought to assess the risk factors as …
Pancreatic Enzyme Replacement Therapy Improves Exclusive Enteral Nutrition Related Diarrhea in Crohn's Disease: A Prospective Randomized Trial
Publication Year: 2025 Source: United European Gastroenterol J PMID: 40243170
BACKGROUND & AIMS: Previous results showed that combined treatment of biologics and exclusive enteral nutrition (EEN) brought moderate-to-severe Crohn's disease patients significant improvements in clinical and endoscopic outcomes. Despite its essential role and favorable safety profile, EEN in the treatment of adult Crohn's disease is frequently underestimated because of lower …
Correction to: Improving Brain-Gut Studies in Crohn's Disease: Methodological Considerations
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 40243178
No Abstract
Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis
Publication Year: 2025 Source: J Crohns Colitis PMID: 40243193
INTRODUCTION: Inflammatory bowel disease management has advanced with therapies like Janus kinase inhibitors (JAKi). Despite their promise, JAKi pharmacokinetic-pharmacodynamic (PK-PD) profiles and tissue-level effects remain underexplored. This study investigates tissue and serum tofacitinib levels, their correlation with therapeutic efficacy, and molecular mechanisms underlying treatment response. METHODS: Thirty refractory ulcerative colitis …
Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease
Publication Year: 2025 Source: Am J Gastroenterol PMID: 40243385 DOI: 10.14309/ajg.0000000000003397
INTRODUCTION: Many patients with inflammatory bowel disease (IBD) experience treatment failures despite availability of effective advanced biologic and small-molecule therapies with differing mechanisms of action. Dual biologic therapy (DBT) is being explored to improve efficacy outcomes and address unmet needs in this difficult-to-treat population. This study aimed to understand patient …
Psychological interventions for treatment of inflammatory bowel disease
Publication Year: 2025 Source: Cochrane Database Syst Rev PMID: 40243391 DOI: 10.1002/14651858.CD006913.pub3
BACKGROUND: Persons with inflammatory bowel disease (IBD) have an increased risk of suffering from psychological problems. The association is assumed to be bi-directional. Psychological treatment is expected to improve quality of life (QoL), psychological issues and, possibly, disease activity. Many trials have tested various psychotherapy approaches, often in combination with …
The Intestinal Macrophage-Intestinal Stem Cell Axis in Inflammatory Bowel Diseases: From Pathogenesis to Therapy
Publication Year: 2025 Source: Int J Mol Sci PMID: 40243444 DOI: 10.3390/ijms26072855
No Abstract
Recent Advances in the Application of Hydrogels as Drug Carriers in Inflammatory Bowel Disease: A Review
Publication Year: 2025 Source: Int J Mol Sci PMID: 40243468 DOI: 10.3390/ijms26072894
Inflammatory bowel disease (IBD) is a chronic and refractory disease with increasing incidence, adversely impacting millions of patients worldwide. Current therapeutic strategies for IBD often exhibit considerable adverse effects, limited efficacy, and a high tendency for recurrence, highlighting the urgent need for novel therapeutic agents. Hydrogel, a three-dimensional hydrophilic network …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide